Menu
Not yet recruiting NCT07383415

Intranasal Platelet-Rich Plasma With or Without Topical Insulin for Post-Inflammatory Anosmia

No phase Interventional Anosmia Inflammatory Anosmia

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Intranasal PRP Plus Topical Insulin, Intranasal PRP Plus Saline (Placebo).
Who it may be relevant to
Registry conditions: Anosmia, Inflammatory Anosmia. Basic parameters: from 19 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Assessing the Effectiveness of Combined Intranasal Platelet-rich Plasma Plus Topical Insulin Versus Platelet-rich Plasma Alone in the Treatment of Post Inflammatory Anosmia: a Randomized Controlled Trial

Overview

This study evaluates whether adding topical insulin to intranasal platelet-rich plasma (PRP) improves smell recovery in adults with post-inflammatory anosmia. Participants will be randomly assigned to receive either intranasal PRP combined with topical insulin or intranasal PRP alone. Changes in olfactory function will be assessed over time to compare the effectiveness and safety of the two treatments.

Detailed description

Post-inflammatory anosmia is a common cause of persistent olfactory dysfunction with limited effective treatment options. Platelet-rich plasma (PRP) has been proposed as a regenerative therapy due to its high concentration of growth factors, while topical insulin has demonstrated potential neurotrophic and anti-inflammatory effects in olfactory tissue.

This randomized controlled trial aims to evaluate whether the addition of topical insulin to intranasal PRP provides greater improvement in olfactory function compared with intranasal PRP alone in adults with post-inflammatory anosmia. Participants will be randomly assigned to receive either combined intranasal PRP plus topical insulin or intranasal PRP alone.

Olfactory function will be assessed at baseline and at predefined follow-up time points using validated smell testing methods. Safety and tolerability of the interventions will also be monitored throughout the study. The results of this study will contribute to understanding the potential role of regenerative and neurotrophic therapies in the management of post-inflammatory anosmia

Interventions

  • Biological Intranasal PRP Plus Topical Insulin
    Autologous platelet-rich plasma administered intranasally with the addition of topical insulin applied to the olfactory cleft.
  • Biological Intranasal PRP Plus Saline (Placebo)
    Autologous platelet-rich plasma administered intranasally with saline applied in place of topical insulin as a placebo comparator.

Primary outcome measures

  • Change in Olfactory Function [Time frame: Baseline to 12 months post-intervention]

Eligibility criteria

Inclusion criteria

  • Diagnosed with olfactory dysfunction despite olfactory training therapy
  • Loss of smell within the past 5 years
  • Loss of smell occurred after an infection
  • Platelet count is over 150,000 platelets per microliter

Exclusion criteria

Have a history of or currently have sinonasal tumours Have a history of surgery or radiotherapy for the base of your skull Have been treated with antibiotics in the past month before surgery Have a condition called systemic vasculitis or any bleeding disorder Have a suspected or known allergy to insulin or PRP or Platelet Lysate (PL) Have inhaled drugs (i.e cocaine) in the past 6 months of your enrollment Smell loss is due to a head trauma or after surgery Unable to complete the Sniffin Stick Smell test or questionnaires

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Single blind
Primary purpose
Treatment

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT07383415 · H25-02495

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗